Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.80%69.291.0%$931.38m
AMGNAmgen Inc.
-0.09%173.140.8%$656.50m
BIIBBiogen Inc.
-0.71%286.900.9%$536.61m
CELGCelgene Corporation
-1.42%119.441.0%$479.99m
REGNRegeneron Pharmaceuticals, Inc.
0.12%371.611.9%$348.38m
ALXNAlexion Pharmaceuticals, Inc.
0.83%129.892.0%$299.57m
TSROTESARO, Inc.
-0.05%190.2715.3%$198.98m
INCYIncyte Corporation
1.55%122.362.3%$170.12m
ILMNIllumina, Inc.
-0.75%162.153.9%$148.02m
VRTXVertex Pharmaceuticals Incorporated
-2.02%86.552.6%$140.07m
CLVSClovis Oncology, Inc.
-4.27%62.9916.4%$132.37m
EXELExelixis, Inc.
-0.04%23.115.5%$131.47m
AAgilent Technologies, Inc.
-0.54%51.351.7%$117.26m
ACADACADIA Pharmaceuticals Inc.
-0.20%39.2019.0%$93.83m
BMRNBioMarin Pharmaceutical Inc.
0.41%90.244.0%$89.98m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.